Clinical Trial Update: A Phase I/Expansion Study of Dasatinib [Phase 1]

View source ↗

Summary

A Phase I/Expansion study of dasatinib for refractory solid tumors and pancreatic adenocarcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Duke University | Conditions: Refractory Solid Tumors, Pancreatic Adenocarcinoma | Phase 1 | Status: TERMINATED